← All trials
NCT02737007
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2016
- Primary completion
- May 12, 2016
- Completion date
- May 12, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
- Hammersmith Medicines ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.